Track topics on Twitter Track topics that are important to you
Health Canada has issued a No Objection Letter in response to IntelGenx’s amended application for its ongoing trial in patients with mild to moderate Alzheimer’s Disease.
The post IntelGenx Receives Authorization for Alzheimer’s Treatment Trial appeared first on Investing News Network.
Original Article: IntelGenx Receives Authorization for Alzheimer’s Treatment TrialNEXT ARTICLE
Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...